Keryx Biopharmaceuticals, Inc. · New York, NY United States (NASDAQ: KERX)
| 750 Lexington Ave., 20th Fl. | Phone: 212-531-5965 |
| New York, NY | Fax: 212-531-5961 |
| 10022 | |
| United States | 
Map This Company |
Keryx Biopharmaceuticals, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Drugs are a life-or-death business for Keryx Biopharmaceuticals. The company specializes in developing treatments for life-threatening ailments, such as cancer and kidney disease. Its lead candidates are Zerenex, a compound that may reduce high phosphate levels in patients with end-stage renal disease, and KRX-0401 (also known as perifosine) to fight renal cell carcinoma and other cancers. Keryx suffered a major blow in 2008 when its previous lead candidate Sulonex failed in a pivotal clinical trial; the drug had been intended to treat diabetic nephropathy, a diabetes-related kidney disease.
Keryx Biopharmaceuticals, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: KERX Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 25 |
Executives
16 executives listed for Keryx Biopharmaceuticals, Inc.'s New York, NY location.
| Chairman | Michael Tarnok | |
|---|---|---|
| CEO and Director | Ron Bentsur | |
| CFO, Treasurer and Corporate Secretary | James Oliviero |